Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Abstract Background To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphine/naloxone (SL-BUP/NLX) are considered the standard of care for OUD in...
Main Authors: | Ismene Petrakis, Sandra A. Springer, Cynthia Davis, Elizabeth Ralevski, Lucy Gu, Robert Lew, John Hermos, Melynn Nuite, Adam J. Gordon, Thomas R. Kosten, Edward V. Nunes, Robert Rosenheck, Andrew J. Saxon, Robert Swift, Alexa Goldberg, Robert Ringer, Ryan Ferguson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-01-01
|
Series: | Addiction Science & Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13722-022-00286-6 |
Similar Items
-
Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings
by: Madeline C. Frost, et al.
Published: (2023-05-01) -
Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
by: Hassan Ziaaddini, et al.
Published: (2018-12-01) -
Buprenorphine Induction Using Microdosing for the Management of Opioid Use Disorder in Pregnancy
by: Neil B. Patel, et al.
Published: (2024-01-01) -
Factors in rural community buprenorphine dispensing
by: Erin G. Major, et al.
Published: (2023-03-01) -
Adapting low-dose buprenorphine induction to meet patient needs: A pilot study
by: Zoe A. Karavolis, et al.
Published: (2022-12-01)